Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.67 |
| ▸ | CBFB | Q13951 | 2/20 | 0.52 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | ATR | Q13535 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8103598 | 0.81 | DYRK1A (0.61) | GRM5XDHDYRK1ANPY5RSYK | |
| SCHEMBL19514104 | 0.81 | KDM4E (0.55) | GRM5CBFBRUNX1NPY5RSCN10A | |
| SCHEMBL4187017 | 0.81 | GRM5 (1.00) | GRM5 | |
| SCHEMBL4190500 | 0.81 | GRM5 (0.67) | GRM5CBFBRUNX1XDHDYRK1A | |
| SCHEMBL31187765 | 0.81 | GRM5 (0.49) | GRM5DYRK1A | |
| SCHEMBL17500184 | 0.81 | GRM5 (0.49) | GRM5DYRK1A | |
| SCHEMBL30117418 | 0.81 | GRM4 (0.51) | GRM5KCNH2 | |
| SCHEMBL22954280 | 0.81 | GRM4 (0.51) | GRM5KCNH2 | |
| SCHEMBL23526602 | 0.80 | GRM5 (0.48) | GRM5DYRK1A | |
| SCHEMBL31083655 | 0.80 | GRM5 (0.48) | GRM5DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802914-B2 | Antifungal compound process | VIAMET PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170081309-A1 | ANTIFUNGAL COMPOUND PROCESS | Mycovia Pharmaceuticals, Inc. | 2017-03-23 | — | — | US | disclosed |
| EP-3119749-A1 | ANTIFUNGAL COMPOUND PROCESS | Viamet Pharmaceuticals, Inc. (US) | 2017-01-25 | — | — | EP | disclosed |
| WO-2015143137-A1 | ANTIFUNGAL COMPOUND PROCESS | VIAMET PHARMACEUTICALS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081309-A1 | ANTIFUNGAL COMPOUND PROCESS | ERG28, DPM1, CYP51A1 | GRM5 3658/4885CBFB 3666/4885RUNX1 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.